PNEUMOCYSTIS-CARINII - IMPROVED MODELS TO STUDY EFFICACY OF DRUGS FOR TREATMENT OR PROPHYLAXIS OF PNEUMOCYSTIS PNEUMONIA IN THE RAT (RATTUS SPP)

被引:40
作者
BARTLETT, MS [1 ]
FISHMAN, JA [1 ]
DURKIN, MM [1 ]
QUEENER, SF [1 ]
SMITH, JW [1 ]
机构
[1] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
关键词
Animal model; Pneumocystis carinii; Pneumonia; Prophylaxis; Relapse; Therapy;
D O I
10.1016/0014-4894(90)90089-U
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Rats which were immunosuppressed with adrenal corticosteroids then transtracheally inoculated with Pneumocystis carinii were evaluated as models for study of drug efficacy. Trimethoprim/sulfamethoxazole, known to be effective against Pneumocystis, was given in therapeutic and prophylactic regimens and its long-term effectiveness determined by a protocol to study relapse. Untreated animals uniformly developed severe infection with differences in numbers of organisms between untreated and treated animals being greater than two logs. Therapy or prophylaxis studies could be completed in 6 to 7 weeks. Animals given prophylaxis or therapy with trimethoprim/sulfamethoxazole had few organisms detected in lungs. Numbers of organisms did not increase during the 4 weeks when the animals were continued on immunosuppression after discontinuing treatment as long as reinfection was prevented. These models are useful for evaluating anti-Pneumocystis activity of antimicrobials. Relapse study data suggest that reinfection may have an important role in development of recurrent Pneumocystis pneumonia. © 1990.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 17 条
[1]   TRIMETREXATE FOR THE TREATMENT OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
ALLEGRA, CJ ;
CHABNER, BA ;
TUAZON, CU ;
OGATAARAKAKI, D ;
BAIRD, B ;
DRAKE, JC ;
SIMMONS, JT ;
LACK, EE ;
SHELHAMER, JH ;
BALIS, F ;
WALKER, R ;
KOVACS, JA ;
LANE, HC ;
MASUR, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (16) :978-985
[2]   NEW RAT MODEL OF PNEUMOCYSTIS-CARINII INFECTION [J].
BARTLETT, MS ;
FISHMAN, JA ;
QUEENER, SF ;
DURKIN, MM ;
JAY, MA ;
SMITH, JW .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (06) :1100-1102
[3]  
BARTLETT MS, 1987, J CLIN MICROBIOL, V9, P1794
[4]  
BARTLETT MS, 1987, J CLIN MICROBIOL, V3, P480
[5]   PROGNOSTIC FACTORS AND LIFE EXPECTANCY OF PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME AND PNEUMOCYSTIS-CARINII PNEUMONIA [J].
BRENNER, M ;
OGNIBENE, FP ;
LACK, EE ;
SIMMONS, JT ;
SUFFREDINI, AF ;
LANE, HC ;
FAUCI, AS ;
PARRILLO, JE ;
SHELHAMER, JH ;
MASUR, H .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (05) :1199-1206
[6]  
CHUSID MJ, 1978, PEDIATRICS, V62, P1031
[7]  
FRENKEL JK, 1966, LAB INVEST, V15, P1559
[8]  
HARON E, 1988, LANCET, P904
[9]  
HUGHES WT, 1979, ANTIMICROB AGENTS CH, V16, P333, DOI 10.1128/AAC.16.3.333
[10]   EFFICACY OF TRIMETHOPRIM AND SULFAMETHOXAZOLE IN PREVENTION AND TREATMENT OF PNEUMOCYSTIS-CARINII PNEUMONITIS [J].
HUGHES, WT ;
MCNABB, PC ;
MAKRES, TD ;
FELDMAN, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1974, 5 (03) :289-293